*仅供医学专业人士阅读参考
*以下内容仅供医疗卫生专业人士浏览。
精彩资讯等你来
参考文献：
[1].Zhang J, Dong Q , Wang Y,et al. Tyrosine kinase inhibitor (TKl) plus PD-1 blockade in TKl-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Results of a multicenter,phase 2 trial (TRAP).2025 #6002.
[2].Zhang W, Zhang Z, Lou S, et al. Efficacy, safety and predictors of combined fruquintinib with programmed death-1 inhibitors for advanced microsatellite-stable colorectal cancer: A retrospective study. Front Oncol. 2022 Aug 31:12:929342.
[3].Li J, Qin S, Xu RH, et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA. 2018;319(24):2486-2496.
[4].Xu R , Qin S, Guo W, et al. Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III trial. Future Oncol. 2021 Apr;17(11):1339-1350.
[5].Dasari A, Lonardi S, Garcia-Carbonero R, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023;402(10395):41-53.
NP-AYT-25N389-Valid Until-2027-May
本资料由和黄医药提供支持
本资料旨在促进医药信息的沟通和交流，而非广告宣传。本资料内容不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。若您想了解更多有关疾病知识的信息，请咨询医疗卫生专业人士。
* 此文仅用于向医学人士提供科学信息，不代表本平台观点
热门跟贴